Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2014-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the safety and immunogenicity of MTBVAC as a potential substitute for BCG vaccination. BCG vaccination has indeed demonstrated its major limitation in inducing protection against tuberculosis (TB). Novel vaccines are essential to fight against the current world epidemics in tuberculosis and resistance to anti-TB drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults

NCT02729571

Tuberculosis

COMPLETED PHASE1/PHASE2

MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa

NCT02933281

Tuberculosis

COMPLETED PHASE1/PHASE2

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.

NCT06272812

Tuberculosis (TB)

RECRUITING PHASE2

Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates

NCT03536117

Tuberculosis

COMPLETED PHASE2

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

NCT04975178

Tuberculosis

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized, double-blind, controlled Phase I study conducted at CHUV, Lausanne, Switzerland, to compare MTBVAC to licensed BCG in healthy, PPD-negative adult male and female volunteers. The study involves random allocation of up to 36 subjects (4 vaccine groups of 9 volunteers fulfilling the inclusion criteria) to MTBVAC (tested at three separate doses) or standard dose BCG (on a 3 verum : 1control basis) in a dose-escalation manner to one of three cohorts. Each cohort includes 9 subjects set to receive MTBVAC lowest dose 5x10E03, or MTBVAC intermediate dose 5x10E04, or high dose 5x10E05 colony forming units (CFU) in 0.1 mL and 3 subjects set to receive standard dose BCG (5x10E05 CFU in 0.1 mL). A single intradermal injection is given in the non-dominant arm of each volunteer starting with the lowest MTBVAC dose. Each MTBVAC vaccine dose is administered staggered by cohort, starting with the cohort with the lowest MTBVAC dose level. After at least 35 days of follow-up within each cohort a safety review and evaluation by Independent Data Safety Monitoring Board provides go/no-go for vaccination of the subsequent cohorts if no safety issues as defined by preset stopping rules.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MTBVAC group 1

Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)

Group Type EXPERIMENTAL

MTBVAC live vaccine

Intervention Type BIOLOGICAL

Live-attenuated Mycobacterium tuberculosis vaccine

MTBVAC Group 2

Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)

Group Type EXPERIMENTAL

MTBVAC live vaccine

Intervention Type BIOLOGICAL

Live-attenuated Mycobacterium tuberculosis vaccine

MTBVAC Group 3

Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)

Group Type EXPERIMENTAL

MTBVAC live vaccine

Intervention Type BIOLOGICAL

Live-attenuated Mycobacterium tuberculosis vaccine

BCG Control Group

Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)

Group Type ACTIVE_COMPARATOR

Commercially available BCG live vaccine

Intervention Type BIOLOGICAL

Live-attenuated Mycobacterium bovis vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MTBVAC live vaccine

Live-attenuated Mycobacterium tuberculosis vaccine

Intervention Type BIOLOGICAL

Commercially available BCG live vaccine

Live-attenuated Mycobacterium bovis vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who the Investigator believes that they can and will comply with the requirements of the protocol
* Subjects who have no evidence of exposition to BCG as demonstrated by a ELISPOT PPD assay along with no history of BCG vaccination and no BCG scar
* A male or female between, and including, 18 and 45 years of age at the time of the vaccination.
* Written informed consent obtained from the subject prior to any study procedure.
* If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception
* Clinically acceptable laboratory values for blood tests.
* Seronegative for human immunodeficiency virus 1 and -2 (HIV-1/2) antibodies, p24 antigen, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibodies.
* No evidence of pulmonary pathology as confirmed by chest X-ray.
* No history of extrapulmonary TB.
* No history of previous contact with M. tuberculosis (latent tuberculosis) as demonstrated by a negative ELISPOT Tb (ESAT-6, CFP10) assay.

Exclusion Criteria

* History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunisations (any vaccine).
* History of allergic disease or reactions
* History of previous administration of experimental Mycobacterium tuberculosis vaccines.
* Use of any investigational or non-registered product (drug or vaccine) in another experimental protocol other than the study vaccines within 30 days preceding the vaccination, or planned use during the study period.
* Any chronic drug therapy to be continued during the study period.
* Chronic administration of immunosuppressors or other immune-modifying drugs.
* Administration of any immunoglobulins, any immunotherapy and/or any blood products within the three months preceding the vaccination, or planned administrations during the study period.
* Any confirmed or suspected immunosuppressive or immunodeficient condition (including HIV) based on medical history and physical examination.
* Any condition or history of any acute or chronic illness or medication which, in the opinion of the Investigator, may interfere with the evaluation of the study objectives.
* A family history of congenital or hereditary immunodeficiency.
* A stay of more than 2 months in a highly endemic area (e.g. Eastern Europe (Romania, Bulgaria) and low-income countries) within 6 months prior to the screening visit or travel of more than 2 months foreseen in an area of high endemicity after the enrolment into the study.
* History of any neurologic disorders or seizures.
* History of chronic alcohol consumption and/or drug abuse.
* Major congenital defects.
* Pregnant or lactating female.
* Female planning to become pregnant or planning to discontinue contraceptive precautions.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes